News and commentary about white-collar crime, enforcement, and compliance
Harry Cassin
Publisher and Editor
Andy Spalding
Senior Editor
Jessica Tillipman
Senior Editor
Richard L. Cassin
Editor at Large
Elizabeth K. Spahn
Editor Emeritus
Cody Worthington
Contributing Editor
Julie DiMauro
Contributing Editor
Thomas Fox
Contributing Editor
Marc Alain Bohn
Contributing Editor
Bill Waite
Contributing Editor
Shruti J. Shah
Contributing Editor
Russell A. Stamets
Contributing Editor
Richard Bistrong
Contributing Editor
Eric Carlson
Contributing Editor
Bill Steinman
Contributing Editor
Last month Forest Labs paid $38 million to settle allegations it paid doctors speaker fees for sometimes phony events so they would prescribe its drugs. It was the latest in a string of “speaker fee” cases.… Continue Reading
A former saleswoman for medical device maker Acclarent was awarded $3.5 million as her share of an $18 million settlement of a whistleblower suit alleging false marketing claims.
Melayna Lokosky made the claims in a complaint filed in federal court in Massachusetts in 2011.… Continue Reading
You might expect corrupt companies to downplay and devalue the principles of market competition. In fact the opposite is true.
Corrupt companies don’t acknowledge that they set out to win business through deliberate criminality.… Continue Reading
Image courtesy of BoeingA plaintiffs law firm that specializes in securities class action litigation was ordered to pay sanctions to Boeing over a lawsuit the firm pressed even though the crucial witness behind it didn’t know anything relevant.… Continue Reading
Reporting companies filed Form SDs with the SEC Monday, and most said its not fully clear if their products contain conflict minerals from Africa’s Congo region.
Tuesday’s print edition of the Wall Street Journal said nearly 1,300 U.S.-listed… Continue Reading
GlaxoSmithKline (GSK) will not be paying doctors to promote its pharmaceutical products through speeches following a corruption scandal in China that was disclosed earlier this year. It will also not make its sales force have individual sales targets any longer.… Continue Reading
The FCPA Blog wanted to explore the idea of the dual-hatted compliance officer — the one who occupies both the general counsel and chief compliance officer roles in a company. We talked with the former SEC Chairman and now Kalorama Partners CEO, Harvey Pitt.… Continue Reading
Health care giant Johnson & Johnson will pay more than $2.2 billion to resolve criminal and civil claims arising from allegations of kickbacks to U.S. doctors and improper marketing claims about three of its prescription drugs.… Continue Reading